Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05779007 · ClinicalTrials.gov registry record
Dose Reduction and Discontinuation With Anti-Fibrotic Medications
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 2,778
- Enrollment target
NCT05779007 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 2,778 participants.
The verdict
NCT05779007 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 2,778 participants
- Enrollment target
Study Summary
The overarching aim of our study is to assess the incidence of dose reduction and discontinuations for pirfenidone and nintedanib.
Interventions
- DRUG Pirfenidone
- DRUG Nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,778 participants |
| Start Date | 2023-04-18 |
| Est. Completion | 2023-07-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05779007
The ClinicalTrials.gov registry entry for NCT05779007 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,778 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pirfenidone is the first listed.
NCT05779007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05779007 about?
NCT05779007 is a clinical study titled "Dose Reduction and Discontinuation With Anti-Fibrotic Medications". The overarching aim of our study is to assess the incidence of dose reduction and discontinuations for pirfenidone and nintedanib.
What is the current status of trial NCT05779007?
This trial is currently completed. The enrollment target is 2,778 participants. The study started on 2023-04-18. Estimated completion is 2023-07-14.
What interventions are being tested in trial NCT05779007?
The interventions under investigation include: Pirfenidone (DRUG), Nintedanib (DRUG).
Who is sponsoring clinical trial NCT05779007?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.